GlassScriptPhysician profile
Adil O Katabay
NPI 1346204039
$4,605.22
in general payments reported to CMS, 2019-2025
38 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $479 · 2021: $336 · 2022: $353 · 2023: $259 · 2024: $2,174 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.83 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,214.99 | 2024 | M22 |
| Collegium Pharmaceutical, INC. | $651.11 | 2019-2025 | Xtampza |
| Protega Pharmaceutials INC | $648.60 | 2024 | Roxybond |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.32 | 2019-2025 | Relistor |
| Abbvie INC. | $247.98 | 2021-2025 | |
| Biodelivery Sciences International, INC. | $218.39 | 2019-2021 | |
| Amgen INC. | $88.85 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $77.34 | 2019 | |
| Merz North America, INC. | $74.96 | 2023 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $71.26 | 2019-2020 | |
| Boston Scientific Corporation | $67.13 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $66.24 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $62.79 | 2023-2024 | Horizant, Horizant |
| Novartis Pharmaceuticals Corporation | $62.08 | 2019-2020 | |
| Abbott Laboratories | $53.83 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.10 | 2019-2020 | |
| Forte Bio-Pharma LLC | $51.13 | 2024 | Prolate, Nalocet |
| Lundbeck LLC | $49.98 | 2020-2024 | Vyepti |
| Si-Bone, INC. | $48.36 | 2021-2023 | |
| Medline Industries LP | $48.23 | 2019 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.00 | 2022 | |
| Currax Pharmaceuticals LLC | $31.67 | 2023-2024 | Contrave |
| Lilly USA, LLC | $26.91 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $24.45 | 2024 | Exparel, Zilretta, Iovera |
| Galderma Laboratories, L.P. | $23.93 | 2023 | |
| Mdd US Operations, LLC | $23.44 | 2019 | |
| Grt US Holding, INC. | $22.50 | 2021-2022 | |
| Allergan, INC. | $19.26 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.74 | 2025 | |
| Genzyme Corporation | $17.52 | 2022 | |
| Averitas Pharma INC. | $16.73 | 2025 | Qutenza |
| Medtronic USA, INC. | $15.19 | 2019 | |
| Zyla Life Sciences, INC. | $13.77 | 2020 | |
| Nevro Corp. | $13.40 | 2019 | |
| Daiichi Sankyo INC. | $12.23 | 2019 | |
| Horizon Therapeutics Plc | $11.93 | 2019 | |
| Supernus Pharmaceuticals, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Katabay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.